NCT01521715 - First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2012

Primary Completion Date

June 30, 2017

Study Completion Date

July 31, 2017

Conditions

Locally Advanced and/or Metastatic Renal Cell CarcinomaCarcinoma, Renal CellClear-cell Metastatic Renal Cell Carcinoma

Interventions

DRUG

Pazopanib

800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.

Trial Locations (8)

17475

Universitätsmedizin Greifswald, Greifswald

30625

Medizinische Hochschule Hannover, Hanover

36043

Medizinisches Versorgungszentrum (MVZ) Osthessen GmbH, Fulda

45122

Universitätsklinikum Essen, Klinik f. Urologie, Essen

48149

Universitätsklinikum Münster, Münster

60590

Med. Klinik II, Johann-Wolfgang-Goethe-Universität, Frankfurt

81377

Ludwig-Maximilians-Universität (LMU) München, Klinikum Grosshadern, München

91054

Urolog. Klinik im Waldkrankenhaus St. Marien, Friedrich-Alexander-Universität, Erlangen